Oric Pharmaceuticals, Inc. (ORIC)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized loss on investments | -22 | |||
| Research and development | 30,549 | |||
| General and administrative | 8,515 | |||
| Total operating expenses | 39,064 | |||
| Loss from operations | -39,064 | |||
| Other income, net | 2,709 | |||
| Net loss | -36,355 | |||
| Comprehensive loss | -36,377 | |||
| Net loss per share, basic | -0.47 | |||
| Net loss per share, diluted | -0.47 | |||
| Weighted-average shares outstanding, basic | 78,126,257 | |||
| Weighted-average shares outstanding, diluted | 78,126,257 | |||